Articles About Uncategorized

You Won’t Sweat Your Next Gut Check With These Three Tactics

0 | By Michael A. Robinson

The tech-centric Nasdaq Composite index hit a new all-time high on July 20. It was the Nasdaq’s 10th straight winning session.

The rest of the market is doing well, too. Last week marked the 27th new high for the S&P 500 this year, making 2017 one of the index’s best years in decades.

This historic bull market is now entering its ninth year.

And so, I know that many of you have been holding onto your cash and hoping for a selloff to lower prices.

You’re not alone. The Wall Street Journal reports that fund managers have increased their cash holdings by 10% this month, to 4.9% of assets.

I understand that impulse.

But I hope you’re not so inclined.

Because if you sat out the year so far, you left a lot of money on the table.

You know that now.

I’m here to tell you today that it’s still not too late to make your move.

But I know that will take a “gut check.”

That’s why I’m showing you three tools that will make that “gut check” easier.

They’ll keep you in the market – and give you the confidence you need to keep making big gains with tech stocks…

At the risk of sounding like a broken record, I can’t say it often enough – the Road to Wealth Is Paved by Tech. And I can prove it…

Since the bull market began on March 9, 2009, the Nasdaq is up 346%. That’s more than 50% better than the S&P’s return over the period.

And it’s all because of the new Convergence Economy we’ve been talking about here for some time now. These days, every business is a tech business, meaning the sector will beat the overall market for years to come.

Having said that, however, it bears noting that no stock, sector, or market rises in a straight line forever. Sooner or later, the market will lose steam.

Let me be clear. I see plenty of upside ahead through the end of 2017. And it bears repeating this is not the time to horde cash and hope for better prices.

Instead, you want to be in tech stocks. And if you use these three Gut Check Tools, you can invest with confidence – and protect your market-crushing gains.

Take a look…

Huge Arenas, Global Audiences, Big Profits

0 | By Michael A. Robinson

There’s not a major sports league in the world today that wouldn’t love to undergo 138% growth in just four years.

We’re talking a total of 238 million viewers around the world for a “sport” that didn’t really hit its stride until 2010.

To cash in on this fast-growing trend, a group of owners from the National Football League, National Basketball Association, and Major League Baseball recently invested more than $140 million to start their own teams.

And if the players look more like computer geeks than athletes, it’s because that’s just what they are. In the new field of eSports, teams duel it out over computer games while fans watch online or at major arenas.

Here’s the thing. Though the field is new, it’s already ripe for disruption due to the immersive experience of virtual reality (VR).

Today, I’m going to reveal a VR firm that offers us a rare Convergence Economy play on the emerging lucrative mix of sports and digital tech.

Let’s get started…

When AI Meets Biotech, the Results Are Amazing – and Profitable

0 | By Michael A. Robinson

In biotech, one thing isn’t going to change.

The treatment that makes up 90% of the pharmaceutical market – good, old-fashioned small molecules created in the laboratory – isn’t going anywhere.

Yes, incredibly innovative treatments like T-cell therapy, microbiome therapies, and CRISPR gene editing are all having a huge impact on healthcare.

But we use small, synthetic molecules to create everything from aspirin and corticosteroids to sofosbuvir (Sovaldi) and ivacaftor (Kalydeco) – and we’ll keep doing so for a long time to come.

The small molecule technique dates back to the 1890s, but that doesn’t mean innovation cannot happen within that field. Scientists are hard at work in the labs, creating cutting-edge drugs, often tailored to treat a very specific disease or subset of patients.

Meanwhile, I’ve turned up a small British company that’s using its artificial intelligence platform to discover promising small molecule treatments faster – and cheaper – than ever before.

I call it biointelligence.

It’s a perfect illustration of the “Convergence Economy” we talk so much about here. By combining two or more fields of tech – in this case biotech and AI – it’s like a formula in which 1 + 1 = 3… and often a lot more that.

Today, we’re going to learn all about this tiny company and its brand-new biointelligence technology.

This company is privately held – so if you ask, Wall Street will say you can’t invest in it.

But I’ve a way you can.

In fact, I’ve found two ways.

Both of them will lead you to outsized returns – and hefty dividends.

Let’s take a look…

Three Biotech Bargains to Buy Right Now

0 | By Michael A. Robinson

Back in October, I did something crazy.

That’s when I told the paid-up members of my Radical Technology Profits trading service to buy a small-cap biotech stock.

Here’s why that move was a bit nuts.

At the time, it looked like Hillary Clinton would soon enter in the White House and clamp down on drug prices – and so the biopharmaceutical sector was deeply out of favor.

Turns out, however, our crazy bet paid off.

Despite his campaign rhetoric, President Donald Trump has pulled back from his own fiery rhetoric about drug-price caps.

That helped pushed biotech and drug stocks into a big uptrend.

And my paid-up members made peak gains of 116% – in just over eight months.

Today, things have changed – and investing in biopharma stocks is generally seen as a smart move. However, that means a lot of these shares have been bid up, and your best move is to buy big winners at deep discounts.

But to do that, you have to know how to find those deals.

I do.

Today I’ll show you how you can, too.

And I’ll reveal the three best Biotech Bargains out there right now

All three have triple-digit gains potential…

Laser Arms Race Gives Savvy Defense Play Even More Firepower

0 | By Michael A. Robinson

Defense stocks are one of the smartest buys of the Trump White House era, given his stated commitment to boosting defense spending by $54 billion.

As we’ve seen, drones and autonomous vehicles are two high-profit ways to play the growth energizing this $1.7 trillion sector.

But the big play – the really disruptive, transformative 21st-century technology – is military lasers.

We’re talking “ray guns” here.

It sounds like science fiction, but it’s a reality. Laser weapons are here now, and, perhaps as soon as next year, they’ll change the way the U.S. military fights conflicts all over the world.

You’ll have reaped the financial rewards long before that, though. That is, if you make one critical play…

Supercomputing Supplier to Rake in Profits From U.S.-China Chip War

0 | By Michael A. Robinson

If you think China‘s tech sector is all about playing copycat, think again.

The United States has fallen behind in a key field after leading for It lies at the heart of such cutting technologies as Artificial Intelligence, machine learning, Big Data, even cracking the mysteries of the universe.

Of course, I’m talking about supercomputing. You see, China unveiled the world’s fastest computing last year. And in a slap in the face for Silicon Valley, did so without U.S. chips.

That’s why on June 14, the U.S. Department of Energy (DoE) said it will provide a three-year, 258 million grant to six American tech leaders. The goal is simple: reclaim the top spot from China.

Doing so includes not just computing, but advances in the brains that runs these machines and semiconductors.

Today, I’m going to reveal five reasons why a leading chip supply firm will make out like gangbusters no matter who wins the race…

Nobody Is Talking About the Best Tech Play After Amazon’s Big Buy

0 | By Michael A. Robinson

If there’s one thing you can count from Wall Street, its repetitious analysis of big tech news.

Take the Amazon.com Inc. (Nasdaq: AMZN) purchase of Whole Foods Market Inc. (Nasdaq: WFM) for $13.2 billion last week.

A steady, predictable stream of stories quoting analysts about the “death of retail” followed the announcement.

Don’t get me wrong – that’s a big, ongoing story. It’s one I wrote about in the past, as recently as May 23.

What they missed is how this is a boon for technology: mobile commerce, Big Data, machine vision and learning, chips, sensors… and especially robots.

Robots already are all over Amazon’s warehouses and are a big part of its success.

Now they’ll be in Whole Foods’ warehouses, checkout lines, and maybe even a part of making deliveries.

You could buy Amazon – and I recommend you do establish a position if you haven’t yet – but that’ll cost you.

You could buy a robotics stock, but that will only scratch the surface.

Or you could make this one move and get at least double the market’s return

One New Investment Could Challenge the Greatest Stock Gain in Decades

0 | By Michael A. Robinson

As I noted during our May 30 chat, the 49,000% gain for Amazon.com Inc. (Nasdaq: AMZN) from the time it went public made it the most successful stock in decades.

That amazing rise shows the power of our tech-centric economy.

Today, I want to talk to you about an investment that’s quickly giving Amazon a run for its money… in a fraction of the time.

It’s not a stock, but it is an investment I personally recommended.

Almost no one on Wall Street or in the financial press believed in the cryptocurrency Bitcoin back in 2013. At the time, Bitcoin was subject of a steady stream of negative stories.

Almost of all of it had one basic – yet incorrect – premise: that Bitcoin was a passing fad that was bound to hurt investors.

But had you bought Bitcoin back when I first talked about it, holding through its many ups and downs, you could have made peak gains of 2,850% in just 4.5 years.

That’s why I’m so excited to tell you about this new breakout technology

The One Statistic All “Pot Stock” Investors Should Know

0 | By Michael A. Robinson

Oakland, Calif. – Now that I’m on my way home from the Fourth Annual Cannabis Business Summit & Expo, there’s one statistic I just can’t stop thinking about.

And that’s a big deal.

You see, people throw around a ton of numbers at these conferences. But their true values can be incredibly opaque.

Whether the data you pick up on the Expo floor is from an entrepreneur, a lobbyist, a politician, an investment analyst, a researcher, a salesperson, or even a “brand representative,” you’ve got to do some work with it.

You’ve got to put it under the microscope, turn it around in your head, and figure out what it truly means. While most of the “tips” you get are just noise, many are interesting enough to share with friends.

But only a very, very few are truly valuable.

I’m talking about a number or statistic that flips a switch in your brain – and points your way toward future profits in your investment portfolio.

And the one number that stuck with me is this – 25%.

Here’s why…